HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raised the price target from $48 to $55.
August 13, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Dyne Therapeutics and raised the price target from $48 to $55.
The raised price target and maintained Buy rating from a reputable analyst firm is likely to positively impact investor sentiment and drive short-term price appreciation for Dyne Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100